Article

Artiflex and I-Care phakic IOLs are accurate; some complications exist with both, study finds

Lisbon, Portugal - Both the Artiflex (Ophtec) iris-claw IOL and the I-Care (Cornéal) phakic angle-supported IOL are effective and provide good refractive outcomes, Antonio Marinho, MD, reported Monday at the European Society of Cataract and Refractive Surgeons meeting.

Lisbon, Portugal - Both the Artiflex (Ophtec) iris-claw IOL and the I-Care (Cornéal) phakic angle-supported IOL are effective and provide good refractive outcomes, Antonio Marinho, MD, reported Monday at the European Society of Cataract and Refractive Surgeons meeting.

Over the long term, however, the I-Care IOL was associated with some complications, according to Dr. Marinho. He is from Hospital Arrabida, Porto, Portugal.

In a study, 38 eyes of 25 patients (myopia range, –3.5 to –12 D) were implanted with the Artiflex IOL and 17 eyes of 13 patients (myopia range, –7.5 to –18.5 D) with the I-Care IOL.

No patients implanted with either group lost lines of vision and many eyes gained lines, Dr. Marinho reported.

There were no intraoperative complications with the Artiflex IOL; two of the I-Care IOLs were damaged. Two eyes implanted with the Artiflex IOL developed mild uveitis 2 weeks after implantation that resolved with treatment. Two months after implantation of the I-Care IOL, the IOL rotated in 10 eyes and 18 months after implantation pupil ovalization developed in nine eyes. There were no long-term complications with the Artiflex IOL.

“Both of the IOLs are effective, safe, and stable. Both are implanted with a sutureless surgery. Sizing is still an issue for me with the I-Care IOL; the new model may solve this problem. [With] the Artiflex there were no complications, but I advise prescribing steroids for a few days,” he concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.